2023
Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis
Lawler P, Manvelian G, Coppi A, Damask A, Cantor M, Ferreira M, Paulding C, Banerjee N, Li D, Jorgensen S, Attre R, Carey D, Krebs K, Milani L, Hveem K, Damås J, Solligård E, Stender S, Tybjærg-Hansen A, Nordestgaard B, Hernandez-Beeftink T, Rogne T, Flores C, Villar J, Walley K, Liu V, Fohner A, Lotta L, Kyratsous C, Sleeman M, Scemama M, DelGizzi R, Pordy R, Horowitz J, Baras A, Martin G, Steg P, Schwartz G, Szarek M, Goodman S. Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis. Critical Care Explorations 2023, 5: e0997. PMID: 37954898, PMCID: PMC10635596, DOI: 10.1097/cce.0000000000000997.Peer-Reviewed Original ResearchProprotein convertase subtilisin/kexin type 9Convertase subtilisin/kexin type 9Subtilisin/kexin type 9Human cohort studiesODYSSEY OUTCOMESCohort studyType 9Isotype-matched controlExperimental murine modelSepsis ratePCSK9 inhibitionPCSK9 inhibitorsSepsis complicationsSepsis mortalitySepsis outcomeImproved survivalBacterial sepsisClinical outcomesBloodstream clearanceSepsis modelClinical trialsOdds ratioCardiovascular diseasePretreatment settingSepsis diagnosis
2018
Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab
Ridker PM, Rose LM, Kastelein JJP, Santos RD, Wei C, Revkin J, Yunis C, Tardif JC, Shear CL, Investigators S. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. Journal Of Clinical Lipidology 2018, 12: 958-965. PMID: 29685591, DOI: 10.1016/j.jacl.2018.03.088.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Anti-IdiotypicAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipoproteinemia Type IIMaleMiddle AgedPlacebo EffectProportional Hazards ModelsProprotein Convertase 9Risk FactorsConceptsProprotein convertase subtilisin kexin type 9Major adverse cardiovascular eventsAdverse cardiovascular eventsPCSK9 inhibitionNon-FH patientsFH patientsCardiovascular eventsFamilial hypercholesterolemiaMean (SD) baseline LDL-C levelElevated low-density lipoprotein cholesterolFuture cardiovascular event ratesBaseline LDL-C levelsLow-density lipoprotein cholesterolSubtilisin kexin type 9Cardiovascular event reductionHard cardiovascular eventsHard cardiovascular outcomesPlacebo-controlled dataPrimary prevention patientsCardiovascular event ratesLDL-C reductionProportion of patientsClinical trial programLDL-C levelsIncidence rate ratios
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply